Cytokinetics Inc (NAS:CYTK)
$ 48.98 0 (0%) Market Cap: 5.14 Bil Enterprise Value: 5.27 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc at JMP Securities Life Science Conference Transcript

Jun 19, 2019 / 01:00PM GMT
Release Date Price: $11.14 (+0.91%)
Jason Butler
JMP Securities - Analyst

Let's go ahead and get started here. Thank you, everybody, again for being with us this morning at the 2019 JMP Securities life science conference.

Excited to have with us now Cytokinetics. Cytokinetics is a company that we have followed for many years, developing novel drugs focused on muscle biology. Lead program Omecamtiv in Phase 3 development for the treatment of heart failure. And there's a building now pipeline of follow-on compounds in cardiovascular medicine as well as the work you are doing in neuromuscular diseases.

So very happy to have the Company's CEO Robert Blum. Robert, thank you for being with us this morning and looking forward to the conversation.

Robert Blum
Cytokinetics, Incorporated - President and CEO

Thank you, Jason. Thank you to those of you gathered here and also on the webcast. I will be making -- I will be presenting a few slides before we get into our conversation and I will be speaking about the Company as it is a pioneer and leader in the area of muscle biology. On this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot